Literature DB >> 16474262

The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits.

Ronald J Ozminkowski1, Wayne N Burton, Ron Z Goetzel, Ross Maclean, Shaohung Wang.   

Abstract

OBJECTIVES: The objectives of this study were to estimate medical expenditures, absenteeism, and short-term disability costs for workers with rheumatoid arthritis (RA) and to estimate the relative costs of RA over a 12-month period.
METHODS: Using data from nine U.S. employers, direct and indirect costs for 8502 workers with RA were compared with costs for a matched group without RA. Regression analyses controlled for factors that were different even after propensity score matching.
RESULTS: Average total costs for workers with RA were $4244 (2003 dollars) greater than for workers without RA. RA was the fourth most costly chronic condition per employee compared with cancers, asthma, bipolar disorder, chronic obstructive pulmonary disease, depression, diabetes, heart disease, hypertension, low back disorders, and renal failure.
CONCLUSIONS: RA is a costly disorder and merits consideration as interventions are considered to improve workers' health and productivity.

Entities:  

Mesh:

Year:  2006        PMID: 16474262     DOI: 10.1097/01.jom.0000194161.12923.52

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  15 in total

Review 1.  Disability and disability-adjusted life years: not the same.

Authors:  Scott D Grosse; Donald J Lollar; Vincent A Campbell; Mary Chamie
Journal:  Public Health Rep       Date:  2009 Mar-Apr       Impact factor: 2.792

2.  Gammaglobulins, autoantibodies, therapeutic antibodies and anti-drug antibodies in rheumatoid arthritis.

Authors:  J-E Gottenberg
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

3.  Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.

Authors:  Howard G Birnbaum; Crystal Pike; Ritesh Banerjee; Tracy Waldman; Mary Cifaldi
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

4.  Patient medication adherence: the forgotten aspect of biologics.

Authors:  Erica L Goldberg; Mitch Dekoven; Vernon F Schabert; Atharine Coyle
Journal:  Biotechnol Healthc       Date:  2009-06

5.  State-level estimates of cancer-related absenteeism costs.

Authors:  Florence K Tangka; Justin G Trogdon; Isaac Nwaise; Donatus U Ekwueme; Gery P Guy; Diane Orenstein
Journal:  J Occup Environ Med       Date:  2013-09       Impact factor: 2.162

Review 6.  Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications.

Authors:  Travis O Bruce
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

7.  Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate.

Authors:  Won-Seok Lee; Sang-Il Lee; Myeung-Soo Lee; Sung-Il Kim; Shin-Seok Lee; Wan-Hee Yoo
Journal:  Korean J Intern Med       Date:  2016-03-10       Impact factor: 2.884

8.  An Advanced Clinician Practitioner in Arthritis Care (ACPAC) Maintains a Positive Patient Experience While Increasing Capacity in Rheumatology Community Care.

Authors:  Vandana Ahluwalia; Taucha Inrig; Tiffany Larsen; Rachel Shupak; Tripti Papneja; Arthur Karasik; Carol Kennedy; Katie Lundon
Journal:  J Multidiscip Healthc       Date:  2021-06-03

9.  Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults.

Authors:  Daniel Polsky; Machaon Bonafede; Jose A Suaya
Journal:  BMC Health Serv Res       Date:  2012-10-31       Impact factor: 2.655

10.  Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds.

Authors:  Vibeke Strand; Mark Kosinski; Ari Gnanasakthy; Usha Mallya; Shephard Mpofu
Journal:  Health Qual Life Outcomes       Date:  2014-03-05       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.